Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Mutational Signature Portal (mSigPortal) for Cancer Genomics Studies

The figure visualizes the mutational processes of tumors from the PCAWG study using mSigPortal

The figure visualizes the mutational processes of tumors from the PCAWG study using mSigPortal.

The Integrative Mutational Signature Portal for Cancer Genomic Studies (mSigPortal) facilitates the investigation of tumor mutational signatures to elucidate endogenous and exogeneous processes involved in tumorigenesis. 

mSigPortal was developed by Tongwu Zhang, Ph.D., and Maria Teresa Landi, M.D., Ph.D., in collaboration with the NCI Center for Biomedical Informatics and Information Technology.  

Website Link

Link to web based tool

Source code is available in Github under MIT license, an Open Source Initiative approved license. 

Support

Questions can be directed to the mSigPortal support email

Reference

Zhang T, et al. Integrative mutational signature portal (mSigPortal) for cancer genomic study (manuscript in preparation). 

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Mutational Signature Portal (mSigPortal) for Cancer Genomics Studies was originally published by the National Cancer Institute.”

Email